Eikon Therapeutics, Inc., was incorporated in Delaware on July 9, 2019. The company is a late-stage clinical biopharmaceutical company that develops innovative medicines to address significant unmet medical needs. The organization focuses primarily on oncology, advancing a range of drug candidates designed to meet high unmet needs in large indications. This leadership team has a remarkable history of successful development of impact drugs. The company's strategy includes leveraging proprietary technology platforms to create new therapies, with its main drug candidates targeting serious diseases such as advanced melanoma and non-small cell lung cancer.